TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, released clinical data from its Phase 1a trial of TTX-MC138 in poster 1025P at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The ongoing multicenter, open-label study evaluates safety, tolerability, pharmacokinetics, antitumor activity and exploratory biomarkers in patients with previously treated advanced solid tumors.
TTX-MC138 was administered once every 28 days across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. The trial met its primary safety endpoint, with no dose-limiting toxicities observed and dose-dependent plasma exposure demonstrated across all evaluated doses. The company also reported disease stabilization and extended progression-free intervals in a subset of patients, supporting continued clinical evaluation of TTX-MC138.
The results matter because TTX-MC138 targets microRNA-10b, a well-documented biomarker of metastasis, in patients with advanced solid tumors who have already received prior treatment. Demonstrating a clean safety profile and dose-dependent exposure at this stage is a key step for any oncology candidate, as it allows the company to proceed with further testing. The observation of disease stabilization and extended progression-free intervals in a subset of patients provides early signals of antitumor activity that warrant additional study.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
For investors and industry observers, the announcement offers a clearer view of the compound's early clinical profile. The full press release can be viewed at https://ibn.fm/g3E2F, and the latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ. Additional information about TransCode Therapeutics is available via TransCode Therapeutics (NASDAQ: RNAZ).
The release was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides services including editorial syndication to 5,000+ outlets, press release enhancement, social media distribution and corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
